Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1026706 in Male and Female Healthy Subjects and Patients With Osteoarthritis of the Knee (Randomised, Double-blind, Placebo-controlled Within the Dose Groups, Clinical Phase I)
Phase of Trial: Phase I
Latest Information Update: 29 Mar 2019
Price : $35 *
At a glance
- Drugs BI 1026706 (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 24 Oct 2014 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
- 11 Jun 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 28 May 2014 Planned End Date changed from 1 Sep 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.